Roche Hldg Ltd Spons (RHHBY) 37.4800 $RHHBY OTC Daily

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Roche Hldg Ltd Spons (RHHBY) 37.4800 $RHHBY

OTC Daily Alert Stock Watch - Roche Holding Ltd (OTC: RHHBY)
WorldStockWire - Fri Mar 28, 9:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Update on Glaxo's Mekinist-Tafinlar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:30PM CDT
GlaxoSmithKline came out with disappointing news regarding its Tafinlar-Mekinist combination for BRAF V600 E or K mutation-positive unresectable or metastatic melanoma.

Positive Data on Halozyme Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:50PM CDT
Halozyme presented positive top-line data on HTI-501 for the treatment of cellulite.

ThromboGenics Plays Long Game for Eye Disease
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
ThromboGenics NV recently announced that it received a 3 million euro grant from the Flemish agency for Innovation by Science and Technology to support development of new therapeutics for diabetic macular edema. The new program will complement...

ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).

Xenon and Genentech Establish New Pain Discovery Collaboration
PR Newswire - Wed Mar 26, 5:00AM CDT
Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain. The collaboration leverages Xenon's Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive pain or where individuals have non-precipitated spontaneous severe pain. This new collaboration agreement builds on the strategic alliance established between Xenon and Genentech in 2012 for the discovery and development of compounds and companion diagnostics for the potential treatment of pain.

WPP Acquires Major Stake in Cognifide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 6:00PM CDT
Recently, WPP Digital purchased a majority stake in a UK-based leading digital consultancy, Cognifide, for an undisclosed sum.

Update on Novartis' Xolair and Secukinumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 4:15PM CDT
Novartis (NVS) has a wide range of products and is not dependent on a single product to drive growth. Moreover, the company boasts a robust pipeline.

Today’s Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 25, 8:25AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Halozyme , Exelixis ,...

Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Could Isis Threaten Regeneron and Novartis?
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 22, 10:00AM CDT
Regeneron and Novartis enjoy little competition for their vision-improving drugs Eylea and Lucentis. As a result, sales of Eylea grew to more than $1.8 billion last year, just two years after winning FDA approval in 2011, and sales of Novartis...

FDA Approves Xolair(R) (omalizumab) for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
Business Wire - Fri Mar 21, 1:43PM CDT
--Nearly 50 Percent of Patients Have Inadequate Response to H1-antihistamines, Previously the Only Approved Therapy for CIU(3)

A Major Confidence Boost for this Health Care IT Provider
Seth Robey, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
Veeva Systems is a provider of cloud-based IT solutions tailored specifically for the life sciences. Their "industry cloud", as they call it, allows customers in the health care space to operate more efficiently by putting everything from customer...

Data on Novartis' Afinitor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 5:05PM CDT
Novartis announced additional results from a phase III trial, BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) on breast cancer drug, Afinitor.

Prothena Surges on Clinical Data Hopes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 10:00AM CDT
Prothena Corporation surged after the company announced that data from a phase I study on NEOD001 will be presented at the ISA.

Specialty Enzymes Market by Source, Type, Application & Geography - Global Trends & Forecasts to 2018
M2 - Thu Mar 20, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cpjrtc/specialty_enzymes) has announced the addition of the "Specialty Enzymes Market by Source, Type, Application & Geography - Global Trends & Forecasts to 2018" report to their offering. Specialty enzymes are natural proteins produced from micro organisms, plants and animals. An enzyme serves as catalysts for the chemical process that include the production of pharmaceuticals, diagnostics, research & biotechnology, and biocatalytic solutions. Enzymes increase reaction rates by decreasing the amount of energy required to form a complex of reactants that is competent to produce reaction products. Specialty enzymes according to their type are classified as carbohydrases, proteases, polymerases and nucleases, lipases, and others. Specialty enzymes report covers analysis of the market structure by identifying various sub-segments of the global specialty enzymes market, Revenue forecasts of the global specialty enzymes markets and its various sub-markets/micro-markets with respect to four main regions- North America, Europe, Asia-Pacific, and Rest of the World (RoW). Major trends, drivers, and restraints of the global specialty enzymes market are identified and explained in detail. The specialty enzyme markets include pharmaceutical, research and biotechnology, diagnostics and biocatalysts. Pharmaceutical manufacturers are witnessing increased awareness in incorporating biocatalysis into manufacturing processes. Enzymes are particularly useful to generate isomerically pure pharmaceuticals and fine chemicals In spite of numerous advantages of biocatalysis, manufacturers have been slow to adopt industrial-scale enzymatic approaches. Key Topics Covered: Introduction Executive Summary Premium Insights Market Overview Global Specialty Enzymes Market, By Source Specialty Enzyme Market, By Type Specialty Enzyme Market, By Application Specialty Enzymes Market, By Geography Competitive Landscape Company Profiles List of Tables List of Figures Companies Mentioned - Advanced Enzyme Technology Ltd. - Affymetrix Inc. - Amano Enzyme Inc. - Basf - Bbi Enzymes Ltd. - Codexis Inc. - Life Technologies - Nagase & Co. Ltd. - Roche Holding Ag. - Sanofi S.A. For more information visit http://www.researchandmarkets.com/research/cp...ty_enzymes About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Why Pfizer Investors Should Watch Quark This Summer
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 19, 1:30PM CDT
Pfizer may learn whether it has a potential challenger to Novartis' and Roche's Lucentis and Regeneron and Bayer's Eylea soon. Its development partner, Quark Pharmaceuticals , is expected to complete its phase 2b study of PF-655 in...

Key Takeaways from Inovio Pharmaceuticals, Inc. Earnings Report
George Budwell, The Motley Fool - Motley Fool - Tue Mar 18, 5:30PM CDT
Most developmental stage biotechs eventually face a 'make or break' moment during the course of their life-cycle. Generally speaking, these key events oft-center around clinical trial data that either validate or sink the company's experimental...

5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...

After Yesterday's Decline of 2.40%, Roche Holding Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 14, 4:06PM CDT
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $36.18 to a high of $36.77. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $36.35 on volume of 5.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 125

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 141

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 50

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
Ivanti's AI Push Rests on Data, Control and Results

Updated Category News Views 216

Enterprise AI has a nasty habit of sounding brilliant right up until it meets a messy fleet of laptops, phones, patches and permissions. Ivanti’s latest product push is aimed squarely at that unglamorous collision point: giving AI systems governed access to the operational data inside Ivanti Neurons, then keeping humans and pre-set permissions in charge of what happens...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 98

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 43

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 141

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Shanghai Import Expo Draws 4,000 Global Companies Again

Updated Category News Views 34

Shanghai spent last week making a rather pointed commercial argument: China wants to be seen buying, not merely selling. The ninth China International Import Expo, or CIIE, brought together more than 4,000 overseas companies and participants from 162 countries, regions and international organizations. That is a serious gathering by any reasonable measure, even if the...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 129

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading